Open Access

PBX1 is a valuable prognostic biomarker for patients with breast cancer

  • Authors:
    • Xiang Ao
    • Wei Ding
    • Hu Ge
    • Yuan Zhang
    • Dan Ding
    • Ying Liu
  • View Affiliations

  • Published online on: April 30, 2020     https://doi.org/10.3892/etm.2020.8705
  • Pages: 385-394
  • Copyright: © Ao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pre-B-cell leukemia transcription factor (PBX) proteins have important roles in the development of numerous organs. To date, four members of the PBX family have been identified to be involved in human cancer but little is known about their expression patterns and precise functions in breast cancer (BC) progression. The aim of the present study was to determine whether they have the potential to be prognostic biomarkers in patients with BC. The expression patterns of PBXs were evaluated using Oncomine, Cancer Cell Line Encyclopedia and Gene expression‑based Outcome for Breast cancer Online algorithm analyses. The prognostic value of PBX1 was determined by Kaplan‑Meier plotter analysis. It was observed that, among all PBX family members, only PBX1 was significantly upregulated in BC vs. normal tissues. Meta‑analysis in the Oncomine database revealed that PBX1 was significantly upregulated in invasive breast carcinoma stroma, ductal breast carcinoma, invasive lobular breast carcinoma, invasive mixed breast carcinoma and male breast carcinoma compared with normal tissues. In addition, PBX1 was significantly correlated with forkhead box protein A1. Subtype analysis indicated that PBX1 overexpression was associated with luminal‑like and hormone receptor‑sensitive subtypes. In the survival analysis, a high expression level of PBX1 was associated with poor prognosis of patients with estrogen receptor (ER)‑positive, luminal A and luminal B subtypes of BC. The results of the present study indicate that PBX1 may serve as a specific biomarker and essential prognostic factor for ER‑positive, luminal A and luminal B subtypes of BC.
View Figures
View References

Related Articles

Journal Cover

July-2020
Volume 20 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ao X, Ding W, Ge H, Zhang Y, Ding D and Liu Y: PBX1 is a valuable prognostic biomarker for patients with breast cancer. Exp Ther Med 20: 385-394, 2020
APA
Ao, X., Ding, W., Ge, H., Zhang, Y., Ding, D., & Liu, Y. (2020). PBX1 is a valuable prognostic biomarker for patients with breast cancer. Experimental and Therapeutic Medicine, 20, 385-394. https://doi.org/10.3892/etm.2020.8705
MLA
Ao, X., Ding, W., Ge, H., Zhang, Y., Ding, D., Liu, Y."PBX1 is a valuable prognostic biomarker for patients with breast cancer". Experimental and Therapeutic Medicine 20.1 (2020): 385-394.
Chicago
Ao, X., Ding, W., Ge, H., Zhang, Y., Ding, D., Liu, Y."PBX1 is a valuable prognostic biomarker for patients with breast cancer". Experimental and Therapeutic Medicine 20, no. 1 (2020): 385-394. https://doi.org/10.3892/etm.2020.8705